Genetic Technology (Precision Breeding) Bill (Fourth sitting)

Debate between Katherine Fletcher and Deidre Brock

Committee stage
Thursday 30th June 2022 Public Bill Committees

[Deidre Brock]

Q We received a briefing from GeneWatch UK, in which it talked about its concerns about a potentially significant impact on trade. As you perhaps know, the Scottish Government are waiting for the EU to complete its consultation on gene editing and GM, and the difference between those two, and whether or not it may allow them to be permissible within Europe as well.

GeneWatch UK said that if exempt GMOs are not traceable—because they are considered to be, as we have heard from several witnesses, the same as conventionally bred organisms—manufacturers should be required to publish a validated test for each GMO released. It suggests that all countries that require such organisms to be regulated could potentially refuse all imports of food and other products that contain that exempt GMO. Could you just expand a little on that for us? I would be interested to hear your points of view.

Lawrence Woodward: If I have understood GeneWatch UK’s position, it is pointing out one of the aspects of this situation, namely that if England proceeds by itself —isolated, without regulatory alignment—that would raise all kinds of trade transparency marketing issues, which are not really addressed and which the Regulatory Policy Committee identified as not being really addressed in the impact statement. You then have dysfunction in regulation and alignment, which leads to confusion in the marketplace, and I think that GeneWatch UK was pointing out the fact that England might allow non-labelling and non-traceability of some of these products would not carry a weight in other markets.

There are many different ways of dealing with that situation. What is absolutely clear is that there needs to be in this Bill greater consideration of traceability throughout the supply chains so that the market can function, and both farmers and consumers have choice. There are different ways of doing that.

GeneWatch UK pointed to the need to develop specific analytical tests. Those analytical tests are being developed. Robin May at the Food Standards Agency pointed out—I think he made some comment that labelling is useless if it cannot be verified. In theory that is true but, first, analytical tests do exist, they are being developed and they can be developed faster. Secondly, we already have in a lot of areas geographical identification and source of origin identification—in egg marketing, whether they are free range eggs or barn eggs. We already have marketing verification based on provenance and audit trails. There is no reason why traceability cannot be built up on that, if the right kind of mandatory information is put in the Bill.

There is a separate discussion about labelling. Obviously, we are in favour of labelling. How that would be, where it is and so on—we recognise the difficulties.

Pat Thomas: To add to that, we have heard a lot over these sessions about how it is not possible to trace these organisms and that simply is not true, particularly for a patented organism. There must be something in place to trace that, in order to protect the patent. So, alongside the development of these organisms, there is also the development of the tests to trace them. The question is whether we will put those into effect or not. I would assume that if the developers want to protect their patents they would want to ensure that those tests are there and available.

[Katherine Fletcher (South Ribble) (Con)]

Q There are a number of things that I think we have heard robust evidence on, but you have clearly spent a lot of time looking at this in a global context. Countries such as Canada, Japan and Argentina are forging forward and allowing their scientists to develop new lines and strains to move forward their agriculture. Do you have any comments on how they are doing it? In all candour, I am worried that, to prevent worries and questions such that you are raising, we almost throttle something that has the potential to be genuinely transformative. What assessment have you made of what Canada, Argentina and Japan, who are forging ahead, are doing?

Lawrence Woodward: People often forget in this conversation that European research establishments overall have made an awful lot of research investment into GMO technology and gene editing technology. Some great work is being done in UK research establishments. It is not that we have a block on this. On how much faster would deregulation, in terms of what is envisaged in the Bill, increase that research activity, others can speak more on that. It is not entirely clear to me that that is the case. It might be a benefit in terms of increasing inward investment from multinational companies.

--- Later in debate ---

[Deidre Brock]

Fascinating. Thank you very much.

[Katherine Fletcher]

Q We spoke in a previous evidence session about the difficulty of codifying the beautiful complexity of biology into law, because biology in and of itself is not in a static state. I think the quote was, “Biology is not physics; it’s not a specific number.” So I am sympathetic to some of the comments that you made earlier. What I want to chase with you is what the consequences of the uncertainty in the drafting are. I cannot understand why someone would want to say that something has been genetically edited when it has not been, and I cannot understand why someone would want to say that something has not been genetically edited when it has been—and that is an expensive process. You have much more experience, so what are the consequences of the uncertainty in the drafting?

Dr Edenborough: The long and the short of it is that a single entity can say different things to different people in different contexts and therefore, in essence, confuse and confound people. You can secure rights in a place by saying one thing and then perhaps avoid liability in another place by saying the opposite.

Genetic Technology (Precision Breeding) Bill

Debate between Katherine Fletcher and Deidre Brock

2nd reading
Wednesday 15th June 2022 Commons Chamber

[Deidre Brock (Edinburgh North and Leith) (SNP)]

The regulation of genetically modified foods is a devolved issue. It is important to emphasise that at the start because, as in a growing number of policy areas, the UK Government pay only lip service at best to the powers exercised in the Scottish Parliament, while at the same time running roughshod over devolution with their post-Brexit deregulatory agenda.

Although the intended scope of the Bill may be England only, it is explicit that it will have significant impacts on devolved areas. The devolved Administrations were, however, only informed of this just one day before the Bill was introduced, in a letter from the Environment Secretary encouraging them to adopt the Bill’s principles. A UK-wide approach can, of course, sometimes be desirable, but this invite creates an illusion of collaboration and choice when in fact DEFRA is acting unilaterally once again. Frankly, it smacks of contempt for our democratically elected Government.

If the Scottish Parliament refused to allow gene-edited crops to be planted in Scotland, we would still be prevented from stopping GMO products from being sold in our shops under the devolution-violating United Kingdom Internal Market Act 2020. This is exactly the kind of scenario the SNP warned against when the Tories forced that legislation through this place. I understand that DEFRA officials have now suggested that the Department discuss the UK Government’s plans to diverge from the common UK-wide GM regulatory regimes. Well, thanks very much, I am sure, but any discussions of that nature should have taken place prior to the introduction of the Bill so that potential policy divergence could be properly considered. The fact that they have not is deeply regrettable and unacceptable.

The SNP is committed to ensuring that Scotland operates to the highest environmental standards, and that we protect and enhance the strength of Scottish agriculture and food production. If we end up with unwanted gene-edited products in Scotland, diverging standards with the EU could cause further damage to our sales, risking damage to Scotland’s reputation for high-quality food and drink.

[Katherine Fletcher]

The way the hon. Lady is talking about gene editing implies that one can tell the difference. It brings in variant genes from the same species. It is literally scientifically impossible to identify a gene-edited product if it is done properly.

[Deidre Brock]

I accept the hon. Lady’s experience in this area, but there are many scientists who would differ from that opinion.